Dräger's Margin Inflection: Customs Refunds and Safety Strength Drive Guidance Raise
Rare double raise at Dräger as EBIT margin nearly quadruples—safety shines while medical still lags.
DRW3.DE · Earnings Call · 2026-07-30
A Turning Point in Lübeck
When Drägerwerk reported its first-half numbers on July 30, the company wasn't just beating expectations—it was rewriting its own financial trajectory. “Thanks to the good operating business, the improved gross margin and some customs refunds, -- our EBIT more than tripled to around EUR 64 million, lifting our EBIT margin to 4.0%.” — Stefan Dräger · 2026-07-30 That's up from 1.3% a year earlier, a nearly fourfold improvement in the group's operating margin. The company has already raised its guidance twice in recent weeks, now targeting an EBIT margin of 6% to 8% for 2026, up from an initial 5.5% floor. The catalyst? A mixture of operational leverage, a favorable product mix, and additional custom refunds that are turning an unplanned tailwind into a margin accelerant. The customs refunds, tied to the controversial IEEPA tariffs imposed on certain imports, are a clear example of a global theme hitting one company's P&L. Dräger has already booked €7.8 million in Q2 and expects another €14.2 million in Q3 after the balance-sheet date, with a potential further €7–9 million on the table. CFO Gert-Hartwig Lescow explained, “Shortly after the half year balance sheet date, we received additional customs refunds of around EUR 14.2 million, including interest payments.” — Gert-Hartwing Lescow, Group CFO · 2026-07-30 While these are one-offs, they provide a bridge to sustainable profitability improvements.Safety Carries the Load, Medical Eyes the Future
The margin expansion would have been far less impressive without the Safety division's relentless momentum. Order intake in Safety surged 9.5% in H1, accelerating to 19.8% in Q2, with EBIT margin rising to 11% from 8% a year ago. CEO Stefan Dräger was unequivocal about the sustainability: “I would absolutely say the development in the profitability and sales growth in the Safety division is sustainable.” — Stefan Dräger · 2026-07-30 The division benefits from strong demand in respiratory protection, gas detection, and occupational health—areas that are increasingly tied to defense spending and industrial safety regulations. therapy devices in Medical are a different story: order intake fell 3.7% in H1, largely due to a massive Mexico hospital infrastructure order in the prior year, but the underlying demand for anesthesia and ventilators appears to be cooling. Medical's net sales still grew 7.6%, but its EBIT remains negative at -€14.3 million, though that's a significant improvement from -€33.7 million. The division is expected to benefit from the recovery of the therapy device market, especially as competitors exit or consolidate. Dräger's focus on service-oriented device connectivity and the upcoming Capital Markets Day signal a deliberate shift toward higher-value, recurring revenue streams.Cost Headwinds and a Strategic Pivot
Not everything is rosy. The Middle East conflict is now hitting Dräger's logistics costs, with an expected impact of up to €10 million this year. CEO Dräger noted, “We see currently higher logistics costs in air and sea freight, where the rates have gone up all over the globe with an expected impact of up to EUR 10 million for the full year 2026.” — Stefan Dräger · 2026-07-30 Yet the company remains confident it can offset these pressures through pricing and cost discipline. The bigger strategic shift is the company's explicit move from sales growth to earnings growth. Dräger has long stated a goal of improving EBIT margin by 1 percentage point per year, targeting 10% by 2030. The latest results put that ambition well within reach.The company is hosting a Capital Markets Day in November to explain its market position and growth levers, suggesting management feels the story is now ripe for investor recognition. Prior calls show Dräger's management has been steadily laying this groundwork. In March 2026, Dräger emphasized the shift toward services and defensive growth: “we crossed the EUR 1 billion threshold in services and some countries in Europe, our sales, the majority already is in services...” — Stefan Dräger, CEO · 2026-03-24 And a year earlier, the focus was on margin normalization: “Q3 was a very good margin... it is safe to assume that will normalize and decline slightly for the Q4 and for the future.” — Stefan Dräger, Chief Executive Officer (CEO) · 2025-10-29 The current quarter's performance, however, defies that caution. The Mexico effect in Medical order intake is a temporary blip, but it underscores the volatility that can obscure underlying demand. Meanwhile, net financial debt has improved to €190 million, and the company's equity ratio is at 52%, providing balance-sheet strength to fund the strategic pivot. Dräger's story is one of a mid-cap medical technology firm that has successfully transformed its operating profile through a focus on profitability, aided by a favorable tailwind from customs refunds. The question now is whether the medical division can follow safety's lead, and whether the 10% margin target becomes a reality earlier than planned.But even without any refunds, which are an unplanned margin tailwind in this year, we are going to perform well in 2026.